Global Blood Therapeutics' voxelotor given breakthrough therapy designation for sickle cell disease Jan. 10, 2018
FDA grants breakthrough therapy designation to Promacta for first-line use in severe aplastic anemia Jan. 4, 2018
BioMarin initiates first phase III study of valoctocogene roxaparvovec for severe hemophilia A Dec. 20, 2017
RSS